Oncolytic Virus Therapy Market Size, Share, Growth and Industry Trends 2035
The Oncolytic Virus Therapy Market is emerging as an important segment of the global oncology industry, driven by increasing cancer prevalence, technological advancements, and growing investment in cancer research. According to WiseGuyReports, the market was valued at USD 2.7 billion in 2024 and is expected to increase from USD 3.0 billion in 2025 to approximately USD 9.8 billion by 2035, representing a CAGR of 12.4% during 2025–2035.
Oncolytic virus therapy uses modified viruses to selectively target and destroy cancer cells while stimulating immune responses against tumors. Advances in genetic engineering and viral modification are improving the selectivity, efficacy, and safety of these therapies. Growing clinical research is also encouraging the development of innovative treatment approaches.
The market is segmented by application, type, route of administration, end user, and region. Key applications include colorectal cancer, melanoma, breast cancer, and lung cancer. Types include viruses, oncolytic virotherapy, and gene therapy, while administration routes include intravenous, intratumoral, and oral approaches.
North America is expected to remain a leading regional market because of advanced healthcare infrastructure, substantial research investment, and the presence of biotechnology companies. Europe and Asia-Pacific are also expected to provide significant opportunities.
Overall, increasing cancer incidence, personalized medicine, clinical trials, and technological innovation are expected to support strong market expansion through 2035.